{"id":"oxypertine","rwe":[{"pmid":"29342497","year":"2018","title":"Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.","finding":"","journal":"The Cochrane database of systematic reviews","studyType":"Clinical Study"},{"pmid":"26051466","year":"2015","title":"Central Nervous System Activities of Indole Derivatives: An Overview.","finding":"","journal":"Central nervous system agents in medicinal chemistry","studyType":"Clinical Study"},{"pmid":"24766970","year":"2014","title":"Chlorpromazine versus every other antipsychotic for schizophrenia: a systematic review and meta-analysis challenging the dogma of equal efficacy of antipsychotic drugs.","finding":"","journal":"European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","studyType":"Clinical Study"},{"pmid":"15519367","year":"2004","title":"Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain.","finding":"","journal":"Life sciences","studyType":"Clinical Study"},{"pmid":"14643514","year":"2003","title":"Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry.","finding":"","journal":"Journal of chromatography. B, Analytical technologies in the biomedical and life sciences","studyType":"Clinical Study"}],"tags":[{"label":"oxypertine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"N05AE01","category":"atc"},{"label":"Active","category":"status"},{"label":"Schizophrenia","category":"indication"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"oxypertin","offLabel":[],"synonyms":["oxypertine","equipertine","oxypertin"],"timeline":[],"approvals":[],"brandName":"Oxypertin","ecosystem":[{"indication":"Schizophrenia","otherDrugs":[{"name":"aripiprazole","slug":"aripiprazole","company":"Otsuka"},{"name":"aripiprazole lauroxil","slug":"aripiprazole-lauroxil","company":"Alkermes"},{"name":"asenapine","slug":"asenapine","company":"Forest Labs Inc"},{"name":"brexpiprazole","slug":"brexpiprazole","company":"Otsuka Pharm Co Ltd"}],"globalPrevalence":24000000}],"mechanism":{"modality":"Small Molecule","drugClass":"oxypertine","explanation":"Imagine your brain is a busy city with many different streets and intersections. Oxypertine helps to calm down some of the busy streets by adjusting the flow of chemical messengers, or neurotransmitters, that carry signals between different parts of the brain. This can help to reduce symptoms of schizophrenia, such as hallucinations and disorganized thinking.","oneSentence":"Oxypertine is thought to work by modulating neurotransmitter activity in the brain.","technicalDetail":"Oxypertine is believed to exert its effects through interaction with specific receptors in the brain, although the exact mechanisms and targets are not well understood."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2035","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OXYPERTINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:14:07.828628","biosimilars":[],"competitors":[{"drugName":"molindone","drugSlug":"molindone","fdaApproval":"1974-01-18","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ziprasidone","drugSlug":"ziprasidone","fdaApproval":"2001-02-05","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"lurasidone","drugSlug":"lurasidone","fdaApproval":"2010-10-28","patentExpiry":"Nov 26, 2026","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"oxypertine","indications":{"approved":[{"name":"Schizophrenia","source":"DrugCentral","snomedId":58214004,"regulator":"FDA","usPrevalence":2800000,"globalPrevalence":24000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2022"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"molindone","brandName":"molindone","genericName":"molindone","approvalYear":"1974","relationship":"same-class"},{"drugId":"ziprasidone","brandName":"ziprasidone","genericName":"ziprasidone","approvalYear":"2001","relationship":"same-class"},{"drugId":"lurasidone","brandName":"lurasidone","genericName":"lurasidone","approvalYear":"2010","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"004015","UNII":"5JGL4G25R7","CHEBI":"CHEBI:31952","INN_ID":"1293","RXNORM":"7815","UMLSCUI":"C0030077","ChEMBL_ID":"CHEMBL2107011","KEGG_DRUG":"D01219","DRUGBANK_ID":"DB13403","PUBCHEM_CID":"4640","SNOMEDCT_US":"349883008","MESH_SUPPLEMENTAL_RECORD_UI":"C084589"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":110,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N05AE01","allCodes":["N05AE01"]},"biosimilarFilings":[],"recentPublications":[{"date":"2018 Jan 18","pmid":"29342497","title":"Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.","journal":"The Cochrane database of systematic reviews"},{"date":"2015","pmid":"26051466","title":"Central Nervous System Activities of Indole Derivatives: An Overview.","journal":"Central nervous system agents in medicinal chemistry"},{"date":"2014 Jul","pmid":"24766970","title":"Chlorpromazine versus every other antipsychotic for schizophrenia: a systematic review and meta-analysis challenging the dogma of equal efficacy of antipsychotic drugs.","journal":"European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology"},{"date":"2004 Nov 26","pmid":"15519367","title":"Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain.","journal":"Life sciences"},{"date":"2003 Dec 25","pmid":"14643514","title":"Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry.","journal":"Journal of chromatography. B, Analytical technologies in the biomedical and life sciences"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxypertin is a small molecule with the synonyms FORIT, INTEGRIN, INTEGRIN (FLAVONE), OXIPERTINA, OXIPERTINE, and OXYPERTINE.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}